Kalaiselvi Natarajan

Kalaiselvi Natarajan

Auto-generated profile, based on publicly available information

Kalaiselvi Natarajan

Institute of Organic Chemistry, Leipzig University, Johannisallee 29, 04103, Leipzig, Germany

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2015 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PDF file
NENagarajan Elumalai
Nagarajan Elumalai
ABAngela Berg
Angela Berg
KNKalaiselvi Natarajan
Kalaiselvi Natarajan
ASAndrej Scharow
Andrej Scharow
TBThorsten Berg
Thorsten Berg
Src homology 2 (SH2) domains play a central role in signal transduction. Although many SH2 domains have been validated as drug targets, their structural similarity makes development of specific inhibitors difficult. The cancer‐relevant transcription factors STAT5a and STAT5b are particularly challenging small‐molecule targets because their SH2 domains are 93 % identical on the amino acid level. Here we present the natural product‐inspired development of the low‐nanomolar inhibitor Stafib‐1, as the first small molecule which inhibits the STAT5b SH2 domain (Ki=44 nM) with more than 50‐fold selectivity over STAT5a. The binding site of the core moiety of Stafib‐1 was validated by functional analysis of point mutants. A prodrug of Stafib‐1 was shown to inhibit STAT5b with high selectivity over STAT5a in tumor cells. Stafib‐1 provides the first demonstration that naturally occurring SH2 domains with more than 90 % sequence identity can be selectively targeted with small organic molecules.

11 April 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
NENagarajan Elumalai
Nagarajan Elumalai
ABAngela Berg
Angela Berg
SRStefan Rubner
Stefan Rubner
LBLinda Blechschmidt
Linda Blechschmidt
CSChen Song
Chen Song
TBThorsten Berg
Thorsten Berg
The transcription factor STAT5b is a target for tumour therapy. We recently reported catechol bisphosphate and derivatives such as Stafib-1 as the first selective inhibitors of the STAT5b SH2 domain. Here, we demonstrate STAT5b binding of catechol bisphosphate by solid-state nuclear magnetic resonance, and report on rational optimization of Stafib-1 (Ki = 44 nM) to Stafib-2 (Ki = 9 nM). The binding site of Stafib-2 was validated using combined isothermal titration calorimetry (ITC) and protein point mutant analysis, representing the first time that functional comparison of wild-type versus mutant protein by ITC has been used to characterize the binding site of a small-molecule ligand of a STAT protein with amino acid resolution. The prodrug Pomstafib-2 selectively inhibits tyrosine phosphorylation of STAT5b in human leukaemia cells and induces apoptosis in a STAT5-dependent manner. We propose Pomstafib-2, which currently represents the most active, selective inhibitor of STAT5b activation available, as a chemical tool for addressing the fundamental question of which roles the different STAT5 proteins play in various cell processes.

10 September 2019 in Chemistry – A European Journal
Verified
Journal Article
Open access
PDF file
KNKalaiselvi Natarajan
Kalaiselvi Natarajan
DMDaniel Müller‐Klieser
Daniel Müller‐Klieser
SRStefan Rubner
Stefan Rubner
TBThorsten Berg
Thorsten Berg
We present a new approach for the identification of inhibitors of phosphorylation‐dependent protein–protein interaction domains, in which phenolic fragments are adapted by in silico O‐phosphorylation before docking‐based screening. From a database of 10 369 180 compounds, we identified 85 021 natural product‐derived phenolic fragments, which were virtually O‐phosphorylated and screened for in silico binding to the STAT3 SH2 domain. Nine screening hits were then synthesized, eight of which showed a degree of in vitro inhibition of STAT3. After analysis of its selectivity profile, the most potent inhibitor was then developed to Stafia‐1, the first small molecule shown to preferentially inhibit the STAT family member STAT5a over the close homologue STAT5b. A phosphonate prodrug based on Stafia‐1 inhibited STAT5a with selectivity over STAT5b in human leukemia cells, providing the first demonstration of selective in vitro and intracellular inhibition of STAT5a by a small‐molecule inhibitor.

1 July 2017 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
NENagarajan Elumalai
Nagarajan Elumalai
KNKalaiselvi Natarajan
Kalaiselvi Natarajan
TBThorsten Berg
Thorsten Berg

27 December 2017 in Beilstein Journal of Organic Chemistry
Verified
Journal Article
Open access
PDF file
RSRobert Szpera
Robert Szpera
NKNadia Kovalenko
Nadia Kovalenko
KNKalaiselvi Natarajan
Kalaiselvi Natarajan
NPNina Paillard
Nina Paillard
BLBruno Linclau
Bruno Linclau
The diastereoselective synthesis of fluorinated building blocks that contain chiral fluorine substituents is of interest. Here we describe optimisation efforts in the synthesis of anti-2,3-difluorobutane-1,4-diol, as well as the synthesis of the corresponding syn-diastereomer. Both targets were synthesised using an epoxide opening strategy.